Biotech startups that raised Series D or later in China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Drug Farm | Shanghai | Series D | $55.0M | 2026-07-13 |
| Vivolight | Nanshanqu | Series E | $13.9M | 2026-06-01 |
| Full-Life Technologies | Shanghai | Series D | $109.0M | 2026-05-18 |
| New Radiomedicine Technology | Chengdu | Series E | $145.4M | 2026-04-03 |
| CORXEL Pharmaceuticals | Shanghai | Series D | $287.0M | 2026-01-22 |
| MAXVAX | Shuangliu | Series D | $27.4M | 2025-12-25 |
| METiS Pharmaceuticals | Hangzhou | Series D | $55.7M | 2025-08-04 |
| IMPACT Therapeutics | Nanjing | Series D | $34.6M | 2024-11-15 |
8 rows of the CSV in 5 of its 18 columns.
- The 74 biotech startups in China whose last round is Series D or later have raised $7.4B in total.
- 16 of them closed their most recent round in the last 12 months, $1.1B combined.
- The largest of those rounds is CORXEL Pharmaceuticals' $287.0M Series D, dated January 2026.
- The most recent is GeneMind Biosciences' $89.5M Series D on 10 September 2026.
- IDG Capital is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 66 companies (89%).
- 4% were founded in 2020 or later; the median founding year is 2013.
- The most common team size is 11 to 50 employees (27% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
11 of 74| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
| Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| MAXVAX | MAXVAX develops and commercializes novel vaccines. | Biotech | Shuangliu | Series D | $27.4M | 2025-12-25 | $284.2M | IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 | 251 to 500 | 2016 |
| METiS Pharmaceuticals | METiS Pharmaceuticals is an AI-driven drug formulation company. | Artificial intelligence | Hangzhou | Series D | $55.7M | 2025-08-04 | $391.7M | Source Code Capital, Frees Fund, Luminous Ventures (former Lightspeed China Partners) | 51 to 100 | 2020 |
| IMPACT Therapeutics | IMPACT Therapeutics develops similar drugs to treat cancer. | Biotech | Nanjing | Series D | $34.6M | 2024-11-15 | BioVenture, Lilly Asia Ventures, Decheng Capital +2 | 51 to 100 | 2009 | |
| Yidao Biotechnology | Yidao Biotechnology researches and develops vaccines and biomedical products. | Biotech | Suzhou | Series D | $25.2M | 2024-05-09 | Qiming Venture Partners, Northern Light Venture Capital | 2017 | ||
| Atom Bioscience & Pharmaceutical | Atom Bioscience is a clinical-stage biotechnology company. | Biotech | Suzhou | Series D | $82.1M | 2023-10-16 | Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 | 11 to 50 | 2012 | |
| DXY Unicorn | DXY is an online healthcare community connecting doctors, consumers, and healthcare organizations. | Biotech | Hangzhou | Series E | $500.0M | 2020-12-29 | $682.0M | Shunwei Capital, DCM Ventures, Legend Capital +1 | 101 to 250 | 2000 |
Table 1. Biotech startups that raised Series D or later in China: the 11 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 74.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| 3 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 4 | Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| 5 | MAXVAX | MAXVAX develops and commercializes novel vaccines. | Biotech | Shuangliu | Series D | $27.4M | 2025-12-25 | $284.2M | IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 | 251 to 500 | 2016 |
| 6 | Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
Table 2. Biotech startups that raised Series D or later in China: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | IDG Capital | Private equity firm | Beijing, China | 2 | 3% | 1 | MAXVAX |
| 2 | EFung Capital | Private equity firm | Shenzhen, China | 2 | 3% | ||
| 3 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 3% | ||
| 4 | South China Venture Capital | Private equity firm | Shenzhen, China | 1 | 1% | 1 | Drug Farm |
| 5 | YD Capital | Private equity firm | Prague, Czech Republic | 1 | 1% | 1 | Drug Farm |
| 6 | BVCF | Private equity firm | Shanghai, China | 1 | 1% | 1 | Drug Farm |
| 7 | DT Capital Partners | Private equity firm | Shanghai, China | 1 | 1% | 1 | Drug Farm |
| 8 | CAS Star | Startup incubator | Xian, China | 1 | 1% | 1 | Vivolight |
| 9 | TusStar | Startup accelerator | Beijing, China | 1 | 1% | 1 | Vivolight |
| 10 | Summer Capital | Private equity firm | Hong Kong | 1 | 1% | 1 | Full-Life Technologies |
| 11 | Sky9 Capital | Venture capital firm | 1 | 1% | 1 | Full-Life Technologies | |
| 12 | Chengwei Capital | Venture capital firm | Shanghai, China | 1 | 1% | 1 | Full-Life Technologies |
| 13 | Prosperity7 Ventures | Venture capital firm | Dhahran, Saudi Arabia | 1 | 1% | 1 | Full-Life Technologies |
| 14 | Chengdu Science and Technology Venture Capital | Venture capital firm | Chengdu, China | 1 | 1% | 1 | New Radiomedicine Technology |
| 15 | Leaps by Bayer | Corporate venture arm | Leverkusen, Germany | 1 | 1% | 1 | CORXEL Pharmaceuticals |
Table 3. Biotech startups that raised Series D or later in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 66 | 89% | $6.6B |
| Software | 4 | 5% | $1.2B |
| Artificial intelligence | 3 | 4% | $529.7M |
| Hardware | 1 | 1% |
Table 4. Biotech startups that raised Series D or later in China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 74 | 100% | $46.9M |
Table 5. Biotech startups that raised Series D or later in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Shanghai | 20 | 27% |
| Beijing | 11 | 15% |
| Hangzhou | 7 | 9% |
| Suzhou | 6 | 8% |
| Nanjing | 3 | 4% |
| Shenzhen | 2 | 3% |
| Wuhan | 2 | 3% |
| Changzhou | 2 | 3% |
| Guangzhou | 2 | 3% |
| Minhang | 2 | 3% |
| Haidian | 1 | 1% |
| Shanhai | 1 | 1% |
Table 6. Biotech startups that raised Series D or later in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 3 | 19% | $208.7M |
| August 2026 | 1 | 6% | $97.1M |
| July 2026 | 2 | 12% | $91.9M |
| June 2026 | 2 | 12% | $60.8M |
| May 2026 | 1 | 6% | $109.0M |
| April 2026 | 1 | 6% | $145.4M |
| January 2026 | 2 | 12% | $294.7M |
| December 2025 | 4 | 25% | $137.5M |
Table 7. Biotech startups that raised Series D or later in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 12 | 16% | $1.0B |
| 2025 | 11 | 15% | $303.4M |
| 2024 | 8 | 11% | $212.7M |
| 2023 | 7 | 9% | $276.0M |
| 2022 | 6 | 8% | $239.0M |
| 2021 | 10 | 14% | $743.5M |
Table 8. Biotech startups that raised Series D or later in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 3 | 4% |
| 2015 to 2019 | 27 | 36% |
| 2010 to 2014 | 27 | 36% |
| Before 2010 | 17 | 23% |
Table 9. Biotech startups that raised Series D or later in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 11 to 50 | 20 | 27% |
| 51 to 100 | 15 | 21% |
| 101 to 250 | 18 | 25% |
| 251 to 500 | 7 | 10% |
| 501 to 1,000 | 10 | 14% |
| 1,001 to 5,000 | 2 | 3% |
| 5,001 to 10,000 | 1 | 1% |
Table 10. Biotech startups that raised Series D or later in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in China. On 16 November 2026 that is 74 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 11 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 74 rows: 16 have no round amount, 0 no city and 16 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in China whose last round is Series D or later are on the list?
- 74, in the file dated 16 November 2026. 16 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 74 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.